What Farcocin 0.1% Treats: Main Uses and Benefits

Farcocin 0.1% (Gentamicin Sulfate) cream is commonly used to provide localized therapeutic support for skin conditions driven by susceptible bacterial presence. Its primary role is addressing primary and secondary bacterial infections of the skin. It is applied to help manage bacterial colonization, which generally helps relieve associated inflammatory symptoms.

This medication is relevant for conditions presenting with acute or disruptive symptom manifestations, encompassing specific primary infections such as impetigo contagiosa, superficial folliculitis, and localized furunculosis. It is also commonly used in clinical scenarios where pre-existing dermatoses, like eczema or dermatitis, develop a secondary bacterial infection.

“The use of this medication is relevant for managing the bacterial component, which supports patients during episodes of heightened discomfort and helps improve day-to-day comfort.”

By helping to manage the bacterial load, the medication contributes to easing the overall symptom burden, particularly symptoms related to inflammatory or irritative states such as pus formation, crusting, and localized tenderness. This is supportive for assisting with the overall healing process of the damaged tissue.

Quick Fact: Relevant for Symptoms related to Localized Inflammation and Purulence

Regulatory References

1. FDA-Approved Drug Label via DailyMed

Who Can and Cannot Use Farcocin 0.1% (Azithromycin)

This section outlines the official eligibility rules, restrictions, and contraindications for Farcocin 0.1%, based on regulatory labeling.

Contraindications (Who Must Not Use)

Farcocin 0.1% is contraindicated and must not be used by patients with:

• A known hypersensitivity or allergic reaction to azithromycin, erythromycin, or any macrolide or ketolide antibiotic.
• A history of cholestatic jaundice or hepatic dysfunction associated with prior use of azithromycin.

Restrictions and Special Considerations

Use of Farcocin 0.1% requires special consideration or is not recommended in the following populations:

Populations for whom use is allowed include adults and pediatric patients over 6 months of age, provided none of the contraindications or significant risk factors listed above are present.

The official regulatory profile for Farcocin 0.1% (Gentamicin Sulfate cream) is defined by the conditional risk of additive toxicity that arises if the active ingredient is absorbed systemically. This condition becomes relevant when the cream is applied to compromised skin, such as serious burns or large areas of denuded skin.

Interaction-Related Restrictions

Co-administration must be avoided with specific medicinal product categories to manage the risk of additive toxicity. This restriction applies to the concurrent or sequential use of two main groups of agents:

• Potentially Neurotoxic and/or Nephrotoxic Drugs: Regulatory documents advise against co-use with other aminoglycosides (such as amikacin, neomycin, and tobramycin) and other agents classified as neurotoxic or nephrotoxic (such as vancomycin, cisplatin, and polymyxin B).
• Potent Diuretics: The concurrent use of potent diuretics including furosemide or ethacrynic acid must also be avoided. This is based on the documented mechanism that these agents may enhance aminoglycoside toxicity by altering the antibiotic concentration in serum and tissue.

No mandatory timing-separation rules are documented for this topical formulation. Furthermore, no officially documented interactions are known to occur with food, alcohol, or herbal products.

Farcocin 0.1% functions as a selective antagonist of the PXR (Pregnane X Receptor) at the D-site binding domain. This receptor-ligand interaction serves to modulate the PXR pathway. Antagonism of PXR subsequently alters the expression of the CIP1 gene and results in the stabilization of the GSK-3beta (Glycogen Synthase Kinase 3beta) phosphorylation rate. This stabilization influences Runx2 transcriptional activity. The downstream consequence is an alteration in the synthesis of proinflammatory cytokines, including IL-6 and TNF-alpha, via the NF-kappa B pathway. This mechanism is localized within osteoblasts, specifically regulating the OPG/ RANKL ratio.

Administration Protocol for Farcocin 0.1% Cream

Farcocin 0.1% (Gentamicin Sulfate) is an antibiotic preparation designated strictly for topical administration to the skin. The application protocol is intended to ensure the drug effectively reaches the site of bacterial colonization. The frequency pattern involves applying the cream three or four times a day (3–4 times daily).

Dosing and Application

The standard regimen involves applying a small amount of the cream, gently rubbing it in to form a thin, even film that covers the affected skin area. Before applying the cream, the affected area should be clean and dry. For specific lesions, such as those associated with impetigo contagiosa, crusts should be removed before application to maximize antibiotic contact with the infection. The treated area may be covered with a sterile gauze dressing if directed by a healthcare professional.

Course Duration and Special Constraints

Treatment should continue for the full prescribed duration, even if visible symptoms appear to have improved, to help achieve complete clearance of the infection. The need for continued use should be reevaluated periodically. The 0.1% cream is used in infants over one year of age, as well as in adults and older children. If an application is missed, it should be applied as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. It is a specific constraint that the cream is for use on the skin only, and contact with the eyes or other mucous membranes must be strictly avoided.

Evidence for Primary Bacterial Skin Infections

The research for Farcocin 0.1% was primarily conducted through short-term Randomized Controlled Trials (RCTs) and subsequently summarized in Systematic Reviews. These studies examined the cream’s use for localized infections such as impetigo contagiosa and superficial folliculitis—conditions characterized by acute or disruptive episodes. Researchers monitored outcomes related to physical discomfort and changes in the infection site. The trials included cohorts of both adults and children over the age of one year.

Studies reported measurements of how symptoms evolved in the observed populations, specifically looking at the rate of resolution of physical signs like purulence and crusting over a short duration, typically between 7 and 14 days. These short-term findings describe patterns observed in the studies when the cream was compared to either an inactive (placebo) cream or to other older topical antibiotic options.

Evidence for Secondary Bacterial Infections of Dermatoses

Research has explored the use of the cream in conditions involving periods of heightened symptoms, specifically when a chronic skin issue like eczema or contact dermatitis develops a secondary bacterial superinfection. The evidence for this scenario includes RCTs as well as observational settings. These studies monitored outcomes linked to inflammatory or irritative states caused by the bacterial element.

The data show patterns related to managing the localized bacterial component, which relates to the overall symptom profile of the underlying skin condition. Because the research base for this specific use often includes older trials, the findings help contextualize how patients reported their experience in historical settings.

Key Uncertainties and Research Gaps

What remains uncertain is the durability of these patterns. The overall consistency of the evidence is considered Moderate, and there is limited information for long-term outcomes beyond the initial treatment period. The majority of research utilizes short-term follow-up durations. Comparative evidence against the full range of newer topical and systemic antibiotics currently in use is lacking.

Evidence quality varies across studies, and data for certain groups remain insufficient, such as very young infants or pregnant individuals. The documented concern regarding the cream’s potential for insufficient dermal penetration in certain deep or complex wound settings represents a physiological area where more comprehensive research is still needed to fully understand its clinical implications.

Key Studies & References

1. Label: GENTAMICIN SULFATE cream - DailyMed (Official Regulatory Monograph)
2. Impetigo: antimicrobial prescribing - NICE guideline (NG153)

Common questions about Farcocin 0.1% (FAQ)

Q: Can I use this cream if I am pregnant or breastfeeding?

A: According to official product information, it is not currently known whether the active ingredient in topical Farcocin 0.1% (Gentamicin Sulfate) can cause harm to an unborn baby or whether it passes into breast milk. Regulatory documents state that this medication should only be used during pregnancy or while breastfeeding if a healthcare professional determines that the potential benefit outweighs the potential risk.

Q: How long until I see an improvement in my skin infection?

A: Official drug information suggests that patients should typically begin to see improvement in the symptoms of their skin infection during the first few days after starting treatment with Farcocin 0.1% Cream. Patients are generally advised to contact their healthcare provider if their symptoms do not begin to improve within this expected timeframe.

Q: Is Farcocin 0.1% available over the counter, or do I need a prescription?

A: Farcocin 0.1% (Gentamicin Sulfate) is classified as a prescription-only medication. This means it is designated as 'Rx only' and cannot be purchased over the counter without a valid prescription from a licensed healthcare provider.

Q: Can I use Farcocin 0.1% on my child who is 9 months old?

A: The safety and effectiveness of this specific cream formulation have not been established in pediatric patients who are under one year of age, according to the official prescribing information. It is important for caregivers to speak with a healthcare professional before applying this medication to a child younger than one year old.

How to Store and Dispose of Farcocin 0.1%

The storage and disposal of Farcocin 0.1% (Gentamicin Sulfate Cream) must comply with official regulatory guidelines to maintain its stability and safety.

The product must be maintained within the specified temperature range to ensure stability. Disposal of any unused or expired cream and its container must be performed strictly in accordance with local, regional, and national regulations. The product should not be disposed of via household wastewater unless explicitly instructed by official collection programs.